Cocrystal Pharma, Inc.COCPNASDAQ
Loading
Net Income Growth Under PressureDecelerating
Percentile Rank49
3Y CAGR-84.4%
5Y CAGR-58.5%
Year-over-Year Change
Year-over-year net income growth rate
3Y CAGR
-84.4%/yr
Quarterly compound
5Y CAGR
-58.5%/yr
Recent deceleration
Percentile
P49
Within normal range
vs 5Y Ago
0x
Contraction
Streak
3 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 0.29% |
| Q2 2025 | 10.69% |
| Q1 2025 | 29.55% |
| Q4 2024 | 33.87% |
| Q3 2024 | 7.56% |
| Q2 2024 | -35.06% |
| Q1 2024 | 11.38% |
| Q4 2023 | -7.18% |
| Q3 2023 | 0.02% |
| Q2 2023 | 19.71% |
| Q1 2023 | -15.29% |
| Q4 2022 | 21.04% |
| Q3 2022 | 76.67% |
| Q2 2022 | -480.51% |
| Q1 2022 | -14.19% |
| Q4 2021 | 6.50% |
| Q3 2021 | -3.14% |
| Q2 2021 | -39.55% |
| Q1 2021 | -83.39% |
| Q4 2020 | 44.08% |
| Q3 2020 | 23.61% |
| Q2 2020 | -75.63% |
| Q1 2020 | 95.84% |
| Q4 2019 | -2587.92% |
| Q3 2019 | -17.49% |
| Q2 2019 | -150.99% |
| Q1 2019 | 106.71% |
| Q4 2018 | -2270.77% |
| Q3 2018 | -39.09% |
| Q2 2018 | 13.52% |
| Q1 2018 | -129.88% |
| Q4 2017 | 329.96% |
| Q3 2017 | -125.55% |
| Q2 2017 | 60.68% |
| Q1 2017 | 96.12% |
| Q4 2016 | -3395.69% |
| Q3 2016 | 41.71% |
| Q2 2016 | 19.57% |
| Q1 2016 | 86.82% |
| Q4 2015 | -5893.90% |